ECSP066752A - Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida - Google Patents
Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamidaInfo
- Publication number
- ECSP066752A ECSP066752A EC2006006752A ECSP066752A ECSP066752A EC SP066752 A ECSP066752 A EC SP066752A EC 2006006752 A EC2006006752 A EC 2006006752A EC SP066752 A ECSP066752 A EC SP066752A EC SP066752 A ECSP066752 A EC SP066752A
- Authority
- EC
- Ecuador
- Prior art keywords
- salt
- methyl
- phenyl
- tartrate
- ilmetile
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 6
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical class [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical class [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 abstract 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 abstract 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 abstract 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 abstract 1
- 150000001860 citric acid derivatives Chemical class 0.000 abstract 1
- 150000004675 formic acid derivatives Chemical class 0.000 abstract 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 abstract 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical class C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- 150000003893 lactate salts Chemical class 0.000 abstract 1
- 229940049920 malate Drugs 0.000 abstract 1
- 150000002690 malonic acid derivatives Chemical class 0.000 abstract 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical class [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 abstract 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 abstract 1
- 150000004727 oxaloacetic acid derivatives Chemical class 0.000 abstract 1
- -1 salt malate Chemical class 0.000 abstract 1
- 150000004760 silicates Chemical class 0.000 abstract 1
- 150000003890 succinate salts Chemical class 0.000 abstract 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 abstract 1
- 150000003892 tartrate salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a las sales de adición de ácido de 4-[4-metil-1-piperazinilmetil]-N-[4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]fenil]-benzamida, que se seleccionan del grupo que consiste de una sal de tartrato, tal como una sal de (D)(-)tartrato o sal de (L)(+) tartrato, sal de clorhidrato, sal de citrato, sal de malato, sal de fumarato, sal de succinato, sal de benzoato, sal de bencensulfonato, sal de pamoato, sal de formiato, sal de malonato, sal de 1,5-naftalendisulfonato, sal de silicato, sal de ciclohexansulfamiato, sal de lactato, sal de mandelato, sal de glutarato acuosa, sal de adipato, sal de escuarato, sal de vanilato, sal de oxaloacetato, sal de ascorbato, y sal de sulfato.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54181704P | 2004-02-04 | 2004-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP066752A true ECSP066752A (es) | 2006-11-16 |
Family
ID=34837520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006006752A ECSP066752A (es) | 2004-02-04 | 2006-08-03 | Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20080249104A1 (es) |
| EP (1) | EP1713792B1 (es) |
| JP (1) | JP4937760B2 (es) |
| KR (2) | KR20060135735A (es) |
| CN (1) | CN100558723C (es) |
| AR (1) | AR047530A1 (es) |
| AU (1) | AU2005211514B2 (es) |
| BR (1) | BRPI0507464A (es) |
| CA (1) | CA2553887C (es) |
| EC (1) | ECSP066752A (es) |
| IL (1) | IL177005A (es) |
| MA (1) | MA28428B1 (es) |
| MY (1) | MY144177A (es) |
| NO (1) | NO20063942L (es) |
| NZ (1) | NZ548714A (es) |
| PE (1) | PE20051096A1 (es) |
| PH (1) | PH12013500157A1 (es) |
| RU (1) | RU2375355C2 (es) |
| TN (1) | TNSN06243A1 (es) |
| TW (1) | TWI347186B (es) |
| WO (1) | WO2005075454A2 (es) |
| ZA (1) | ZA200605972B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
| GT200600316A (es) * | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
| JP5844508B2 (ja) | 2005-11-25 | 2016-01-20 | ノバルティス アーゲー | メシル酸イマチニブのｆ結晶形 |
| KR100799821B1 (ko) * | 2007-02-05 | 2008-01-31 | 동화약품공업주식회사 | 신규한 이마티닙 캠실레이트 및 그의 제조방법 |
| US7550591B2 (en) | 2007-05-02 | 2009-06-23 | Chemagis Ltd. | Imatinib production process |
| WO2008136010A1 (en) * | 2007-05-07 | 2008-11-13 | Natco Pharma Limited | A process for the preparation of highly pure imatinib base |
| WO2009036753A2 (de) * | 2007-09-20 | 2009-03-26 | Schebo Biotech Ag | Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie |
| EP2081556A1 (en) | 2007-09-25 | 2009-07-29 | Teva Pharmaceutical Industries Ltd. | Stable imatinib compositions |
| EP2062885A1 (en) * | 2007-11-21 | 2009-05-27 | Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. | Acid addition salts of imatinib and formulations comprising the same |
| NZ779754A (en) | 2009-01-16 | 2023-04-28 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| US20100189790A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| US20100330130A1 (en) * | 2009-05-22 | 2010-12-30 | Actavis Group Ptc Ehf | Substantially pure imatinib or a pharmaceutically acceptable salt thereof |
| US8431576B2 (en) | 2009-06-25 | 2013-04-30 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| US8933037B2 (en) | 2009-09-28 | 2015-01-13 | Medizinische Universitat Wien | Methods involving PDGFRBETA inhibitors |
| PL389357A1 (pl) | 2009-10-22 | 2011-04-26 | Tomasz Koźluk | Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania |
| KR101138840B1 (ko) * | 2009-12-28 | 2012-05-10 | 주식회사 셀트리온화학연구소 | 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물 |
| KR20130055576A (ko) | 2010-03-15 | 2013-05-28 | 낫코 파마 리미티드 | 고순도의 결정질 이마티닙 염기를 제조하는 방법 |
| EA024088B1 (ru) | 2010-06-18 | 2016-08-31 | КРКА, д.д., НОВО МЕСТО | α-ФОРМА МЕЗИЛАТА ИМАТИНИБА, СПОСОБЫ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЁ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ |
| WO2012090221A1 (en) | 2010-12-29 | 2012-07-05 | Cadila Healthcare Limited | Novel salts of imatinib |
| EP2833866B2 (en) | 2012-04-04 | 2024-11-27 | Intervet International B.V. | Soft chewable pharmaceutical products |
| WO2014016848A2 (en) | 2012-07-24 | 2014-01-30 | Laurus Labs Private Limited | Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof |
| EP3782604A1 (en) | 2013-07-31 | 2021-02-24 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| SI3407874T1 (sl) | 2016-01-25 | 2024-10-30 | Krka, D.D., Novo Mesto | Hitro disperzibilni farmacevtski sestavek, ki obsega zaviralca tirozin-kinaze |
| EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW225528B (es) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| JP3691861B2 (ja) * | 1994-09-14 | 2005-09-07 | 株式会社東芝 | 光ディスク用光パルス幅制御装置 |
| CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US6448293B1 (en) * | 2000-03-31 | 2002-09-10 | Pfizer Inc. | Diphenyl ether compounds useful in therapy |
| GB0019228D0 (en) * | 2000-08-04 | 2000-09-27 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0022438D0 (en) * | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
| US6479692B1 (en) * | 2001-05-02 | 2002-11-12 | Nobex Corporation | Methods of synthesizing acylanilides including bicalutamide and derivatives thereof |
| GB0202873D0 (en) * | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
| US20050124624A1 (en) * | 2002-03-15 | 2005-06-09 | Gilbert Richard E. | 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for threating ang ii-mediated diseases |
| GB2398565A (en) * | 2003-02-18 | 2004-08-25 | Cipla Ltd | Imatinib preparation and salts |
| JP5844508B2 (ja) * | 2005-11-25 | 2016-01-20 | ノバルティス アーゲー | メシル酸イマチニブのｆ結晶形 |
-
2005
- 2005-02-02 PE PE2005000124A patent/PE20051096A1/es not_active Application Discontinuation
- 2005-02-02 MY MYPI20050400A patent/MY144177A/en unknown
- 2005-02-02 AR ARP050100395A patent/AR047530A1/es not_active Application Discontinuation
- 2005-02-03 JP JP2006551802A patent/JP4937760B2/ja not_active Expired - Fee Related
- 2005-02-03 AU AU2005211514A patent/AU2005211514B2/en not_active Ceased
- 2005-02-03 TW TW094103446A patent/TWI347186B/zh not_active IP Right Cessation
- 2005-02-03 KR KR1020067015707A patent/KR20060135735A/ko not_active Ceased
- 2005-02-03 CA CA2553887A patent/CA2553887C/en not_active Expired - Fee Related
- 2005-02-03 NZ NZ548714A patent/NZ548714A/xx not_active IP Right Cessation
- 2005-02-03 EP EP05707165.6A patent/EP1713792B1/en not_active Expired - Lifetime
- 2005-02-03 RU RU2006131548/04A patent/RU2375355C2/ru not_active IP Right Cessation
- 2005-02-03 BR BRPI0507464-9A patent/BRPI0507464A/pt not_active IP Right Cessation
- 2005-02-03 WO PCT/EP2005/001077 patent/WO2005075454A2/en not_active Ceased
- 2005-02-03 CN CNB2005800032177A patent/CN100558723C/zh not_active Expired - Fee Related
- 2005-02-03 US US10/597,287 patent/US20080249104A1/en not_active Abandoned
- 2005-02-03 KR KR1020127025616A patent/KR20120127525A/ko not_active Ceased
-
2006
- 2006-07-19 ZA ZA200605972A patent/ZA200605972B/en unknown
- 2006-07-20 IL IL177005A patent/IL177005A/en unknown
- 2006-08-01 MA MA29225A patent/MA28428B1/fr unknown
- 2006-08-03 TN TNP2006000243A patent/TNSN06243A1/en unknown
- 2006-08-03 EC EC2006006752A patent/ECSP066752A/es unknown
- 2006-09-04 NO NO20063942A patent/NO20063942L/no not_active Application Discontinuation
-
2012
- 2012-02-08 US US13/368,811 patent/US8513256B2/en not_active Expired - Fee Related
-
2013
- 2013-01-22 PH PH12013500157A patent/PH12013500157A1/en unknown
- 2013-07-19 US US13/946,000 patent/US20140051853A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP066752A (es) | Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida | |
| UA84462C2 (ru) | Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой | |
| PE20121476A1 (es) | Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r | |
| ATE321556T1 (de) | Behandlung gastrointestinaler stroma-tumoren | |
| PE20090288A1 (es) | Derivados de quinoxalina como inhibidores de la pi3 quinasa | |
| AR076433A1 (es) | Sales inhibidoras de cdk | |
| TW200714589A (en) | Phenylacetamides suitable as protein kinase inhibitors | |
| AR055613A1 (es) | Formas cristalinas delta y epsilon de mesilato de imatinib | |
| PE20070795A1 (es) | Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa | |
| AR053984A1 (es) | Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas | |
| MY146403A (en) | F, g, h, i and k crystal forms of imatinib mesylate | |
| ECSP077845A (es) | Composiciones y sales dermatológicas para el tratamiento de enfermedades dermatológicas | |
| RU2016146560A (ru) | Производные морфолин-пиридина | |
| TH74677A (th) | รูปเกลือของ 4-[(4-เมทธิลปิปเปอราซิน-1-อิลเมทธิล)-n-[4-เมทธิล-3-(4-ไพริดิน-3-อิล)ไพริมิดิน-2-อิลอะมิโน)เฟนนิล]-เบนซามีด | |
| ATE439133T1 (de) | Verwendung von tyrosin-kinase-hemmern zur behandlung von diabetes | |
| NO20064114L (no) | Fremgangsmate for fremstilling av N-arylpiperazinderivater | |
| NZ602758A (en) | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts | |
| DE602005018171D1 (de) | Verfahren zur herstellung von ziprasidon | |
| ATE492277T1 (de) | Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-( -(pyridin-3-yl)pyrimidin-2- ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms | |
| TH114424A (th) | สารเตรียมชนิดของแข็ง | |
| UY28498A1 (es) | Modificación de cristal de un derivado de n-fenil-2-pirimidinamina, procesos para su fabricación y su uso. | |
| DE60305460D1 (de) | Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen | |
| CY1110806T1 (el) | Μια κρυσταλλικη μεταβαλλομενου βαθμου ενυδατωσης ενυδρη μορφη toy (s)-6-(4-(2-((3-(9η-καρβαζολ-4-υλοξυ)-2-υδροξυπροπυλ]αμινο]-2-μεθυλπροπυλ) φαινοξυ)-3-πυριδινοκαρβοξαμιδιου ημιηλεκτρικο αλας | |
| AR055284A1 (es) | R-enantiomeros de n- propargil- 1- aminoindano, sales, composiciones y usos de los mismos | |
| PL366885A1 (en) | Method for manufacturing crystalline form alpha of additive salt of metanesulphonic acid and 4-(4-methylpiperazin-1-yl methyl)-n-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-yl amine] phenyl] benzamide |